로딩 중…
지수 로딩 중…
CHA Biotech
085660· KOSDAQ· Health Care· Health Care Equipment & Services
₩11,930-1.24%
2026-06-19
Price Chart
CHA Biotech+17.19%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 1.11T KRW |
| Revenue | 1.29T KRW |
| Net Income | -128.52B KRW |
| Total Assets | 2.79T KRW |
| Net Assets | 1.02T KRW |
| Employees | 334 |
| Value | |
| P/B | 1.09x |
| P/S | 0.86x |
| FCF Yield | -19.79% |
| Profitability | |
| ROE | -12.63% |
| ROA | -4.61% |
| Op. Margin | -5.18% |
| Revenue Growth | 8.41% |
| Financial Health | |
| Debt Ratio | 173.82% |
| Total Debt | 1.31T KRW |
| FCF | -219.51B KRW |
| Cash | 347.70B KRW |
| Current Ratio | 0.88x |
| Dividend | |
| Div. Growth | -13.60% |
| Performance | |
| 1Y Return | 17.19% |
| 1M Return | -11.63% |
| From 52W High | -50.19% |
| 1Y MDD | -52.91% |
| Trading | |
| Volume | 732,212 shares |
| Foreign Own. | 8.28% |
| Per Share | |
| EPS | -945 KRW |
| BPS | 5,534 KRW |
Company Info
CHA Biotech, established in 2002, engages in umbilical cord blood banking, stem cell research and cell therapy development, and anti-aging services. Through its major subsidiaries, the company operates pharmaceutical, global CDMO, and global medical network businesses, leveraging an ecosystem-based clinical and new drug development platform. Revenue generation is expected from advanced regenerative medicine treatment sales and global out-licensing. It is also strengthening its global network by establishing the world's largest Cell and Gene Therapy (CGT) manufacturing facility. CHA Biotech is headquartered in Gangnam-gu, Seoul.